Toll Free: 1-888-928-9744

Polycystic Kidney Disease - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 93 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polycystic Kidney Disease - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2017, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Polycystic Kidney Disease - Overview 8 Polycystic Kidney Disease - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 16 Polycystic Kidney Disease - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Polycystic Kidney Disease - Companies Involved in Therapeutics Development 25 Angion Biomedica Corp 25 Aptevo Therapeutics Inc 25 Celgene Corp 26 Conatus Pharmaceuticals Inc 26 DiscoveryBiomed Inc 27 Endocyte Inc 27 IC-MedTech Inc 28 Ipsen SA 28 Kadmon Corp LLC 29 Madrigal Pharmaceuticals Inc. 29 ManRos Therapeutics 30 Metabolic Solutions Development Company LLC 30 Mironid Ltd 30 NovaTarg Therapeutics Inc 31 Otsuka Holdings Co Ltd 31 Q BioMed Inc 32 Regulus Therapeutics Inc 32 XORTX Pharma Corp 32 Polycystic Kidney Disease - Drug Profiles 33 (sodium ascorbate + menadione sodium bisulfite) - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 ANG-3070 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 CIM-2 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 CR-8 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 DBM-43H11 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Drug for Cystic Kidney Disease - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 EC-0371 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 IDN-8050 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 JP-153 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 lanreotide acetate - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 lixivaptan - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 menadione sodium bisulfite - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 MSDC-0160 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 oxypurinol - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 pyrimethamine - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 RGLS-4326 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 ricolinostat - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Small Molecules to Inhibit PDE4 for Polycystic Kidney Disease and Oncology - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 STA-2842 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 tesevatinib tosylate - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 TNFR x TWEAKR - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 tolvaptan - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Polycystic Kidney Disease - Dormant Projects 81 Polycystic Kidney Disease - Discontinued Products 82 Polycystic Kidney Disease - Product Development Milestones 83 Featured News & Press Releases 83 Oct 04, 2017: Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease 83 Jun 12, 2017: Palladio Biosciences Announces Appointment of Frank C. Condella, Jr. to Board of Directors 83 Jun 12, 2017: Regulus Announces Pipeline Update and Advancement on RGLS-4326 84 May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S 84 May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S. 84 Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan 85 Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD 85 Dec 06, 2016: Regulus Announces Update on RGLS4326 85 Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016 86 Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease 86 Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015 87 May 28, 2015: Otsuka's JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease 88 Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented "dual action" small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases 89 Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease 90 Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease 90 Appendix 92 Methodology 92 Coverage 92 Secondary Research 92 Primary Research 92 Expert Panel Validation 92 Contact Us 92 Disclaimer 93
List of Tables
Number of Products under Development for Polycystic Kidney Disease, H2 2017 9 Number of Products under Development by Companies, H2 2017 11 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Universities/Institutes, H2 2017 13 Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15 Products under Development by Universities/Institutes, H2 2017 16 Number of Products by Stage and Target, H2 2017 18 Number of Products by Stage and Mechanism of Action, H2 2017 20 Number of Products by Stage and Route of Administration, H2 2017 22 Number of Products by Stage and Molecule Type, H2 2017 24 Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H2 2017 25 Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H2 2017 25 Polycystic Kidney Disease - Pipeline by Celgene Corp, H2 2017 26 Polycystic Kidney Disease - Pipeline by Conatus Pharmaceuticals Inc, H2 2017 26 Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H2 2017 27 Polycystic Kidney Disease - Pipeline by Endocyte Inc, H2 2017 27 Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H2 2017 28 Polycystic Kidney Disease - Pipeline by Ipsen SA, H2 2017 28 Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H2 2017 29 Polycystic Kidney Disease - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 29 Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2017 30 Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2017 30 Polycystic Kidney Disease - Pipeline by Mironid Ltd, H2 2017 30 Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H2 2017 31 Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co Ltd, H2 2017 31 Polycystic Kidney Disease - Pipeline by Q BioMed Inc, H2 2017 32 Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H2 2017 32 Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp, H2 2017 32 Polycystic Kidney Disease - Dormant Projects, H2 2017 81 Polycystic Kidney Disease - Discontinued Products, H2 2017 82



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify